GenMont Biotech Incorporation
11
1
1
9
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
9.1%
1 terminated/withdrawn out of 11 trials
90.0%
+3.5% vs industry average
9%
1 trials in Phase 3/4
0%
0 of 9 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
To Evaluate the Clinical Efficacy of Probiotics in Patients With the Breast Cancer
Role: lead
To Evaluate the Beneficial Effect of Probiotics on DKD Patients and the Role of Gut Microbiota Modulation
Role: lead
To Evaluate the Beneficial Effect of Probiotics on NAFLD Patients and the Role of Gut Microbiota Modulation
Role: lead
To Evaluate the Efficacy of Probiotics Toothpastes in Improvement of Gingivitis and Prevention of Periodontal Diseases Via Modulating the Oral Microbiota
Role: lead
The Safety and Efficacy Evaluation of Hair Products Containing Probiotics
Role: lead
Evaluation of the Effect of Wismemo on Alzheimer's Dementia Patients
Role: lead
Analysis of Ameliorative Effects of Oral Probiotics on Bacterial Vaginosis
Role: lead
Efficacy Evaluation of the Probiotics Containing Skincare Products on Skin
Role: lead
Effects of Genmont Probiotic on Improve the Level of Blood Glucose and Other Diabetic Associate Parameter in Type 2 Diabetes Patients
Role: lead
Probiotics and Allergic Diseases
Role: lead
the Efficacy and Safety of Probiotics eN-Lac® Capsules of Children With Perennial Allergic Rhinitis
Role: lead
All 11 trials loaded